Clene Inc. Reports Continued Financial Losses in Q3 2025
I'm PortAI, I can summarize articles.
Clene Inc., a clinical-stage pharmaceutical company, reported a net loss of $8.8 million in Q3 2025, up from $8.0 million the previous year. Revenue was minimal at $15,000, and cash reserves fell to $7.9 million. The company faces a stockholders' deficit of $12.4 million and challenges in securing additional financing. Management is implementing cost-saving measures and exploring funding options, but the company's future remains uncertain.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments